BioVaxys: Funding, Investors & Team (Sep 2026)
BioVaxys Technology Corp. is a biotechnology company based in British Columbia that focuses on developing vaccines for viral and oncology diseases, as well as immuno-diagnostics. The company is working on a SARS-CoV-2 vaccine using its unique viral protein technology, and is planning a clinical trial for a cell vaccine in combination with checkpoint inhibitors for ovarian cancer treatment. Additionally, BioVaxys is developing a diagnostic tool to assess T cell immune response to SARS-CoV-2. The company has patents related to its cancer vaccine and is in the process of securing patents for its Covid-19 vaccine and diagnostic technologies.
BioVaxys has raised $3.8M across 6 funding rounds on record, the most recent an undisclosed round of $40k announced in Apr 2025.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
BioVaxys Company Profile and Key Stats
Latest funding round on record: Apr 2025.
BioVaxys Funding Rounds
BioVaxys raised $1.2M in an undisclosed round announced in Jan 2024.
2 months later, an undisclosed round of $1.0M was announced in Mar 2024.
2 months later, an undisclosed round of $280k was announced in May 2024.
6 months later, an undisclosed round of $710k was announced in Nov 2024.
2 months later, an undisclosed round of $540k was announced in Jan 2025.
3 months later, an undisclosed round of $40k was announced in Apr 2025.
BioVaxys Founders and Leadership Team
No contact details are on record for this team yet.
BioVaxys Funding Compared to Other Biotechnology Startups
BioVaxys' latest round of $40k is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like BioVaxys in Biotechnology and New York
Companies Similar to BioVaxys
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
BioVaxys Funding FAQs
What does BioVaxys do?
BioVaxys Technology Corp. is a biotechnology company based in British Columbia that focuses on developing vaccines for viral and oncology diseases, as well as immuno-diagnostics. The company is working on a SARS-CoV-2 vaccine using its unique viral protein technology, and is planning a clinical trial for a cell vaccine in combination with checkpoint inhibitors for ovarian cancer treatment. Additionally, BioVaxys is developing a diagnostic tool to assess T cell immune response to SARS-CoV-2. The company has patents related to its cancer vaccine and is in the process of securing patents for its Covid-19 vaccine and diagnostic technologies.
How much funding has BioVaxys raised?
BioVaxys has raised $3.8M across 6 rounds on record. The most recent is an undisclosed round of $40k announced in Apr 2025.
When did BioVaxys last raise funding?
BioVaxys' most recent funding round on record is an undisclosed round of $40k, announced in Apr 2025.
Who founded BioVaxys?
FundedIQ lists David Berd (Founder) at BioVaxys.
Where is BioVaxys headquartered?
BioVaxys is based in New York, United States.
How many employees does BioVaxys have?
BioVaxys is in the 1-10 employee band.
How does BioVaxys' funding compare to other Biotechnology startups?
BioVaxys' latest round of $40k is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's BioVaxys Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for BioVaxys is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.